| 1 |
Liu T. Potential benefits and risks of interim analyses in clinical studies [J]. NEJM Evid, 2023, 2(7): EVIDe2300124.
|
| 2 |
Bai X, Deng Q. Applying CHW method to 2-in-1 design: gain or lose ?[J]. J Biopharm Stat, 2019, 29 (4): 714- 721.
|
| 3 |
杨笑, 夏雪, 周全, 等. “希望区域”框架样本量重估在适应性设计临床试验中的应用[J]. 首都医科大学学报, 2025, 46 (2): 197- 201.
|
| 4 |
陈垂雄, 王文文, 黄曼丽, 等. 基于期中条件检验效能的希望区域法在临床试验非盲样本量重估中的应用[J]. 空军军医大学学报, 2025, 46 (5): 668- 674.
|
| 5 |
Kunzmann K, Grayling MJ, Lee KM, et al. Conditional power and friends: the why and how of (un)planned, unblinded sample size recalculations in confirmatory trials[J]. Stat Med, 2022, 41 (5): 877- 890.
doi: 10.1002/sim.9288
|
| 6 |
Pilz M, Herrmann C, Rauch G, et al. Optimal unplanned design modification in adaptive two-stage trials[J]. Pharm Stat, 2022, 21 (6): 1121- 1137.
doi: 10.1002/pst.2228
|
| 7 |
Pilz M, Kieser M. New results on optimal conditional error functions for adaptive two-stage designs[J]. J Appl Stat, 2024, 51 (15): 3178- 3194.
doi: 10.1080/02664763.2024.2342424
|
| 8 |
Placzek M, Friede T. A conditional error function approach for adaptive enrichment designs with continuous endpoints[J]. Stat Med, 2019, 38 (17): 3105- 3122.
doi: 10.1002/sim.8154
|
| 9 |
Saville BR, Detry MA, Viele K. Conditional power: how likely is trial success ?[J]. JAMA, 2023, 329 (6): 508- 509.
doi: 10.1001/jama.2022.25080
|
| 10 |
Li X, Yung G, Lin J, et al. Estimation of conditional power in the presence of auxiliary data[J]. Stat Med, 2023, 42 (24): 4319- 4332.
doi: 10.1002/sim.9863
|
| 11 |
Liu Q, Hu G, Ye B, et al. Sample size re-estimation in Phase 2 dose-finding: conditional power versus Bayesian predictive power[J]. Pharm Stat, 2023, 22 (2): 349- 364.
|
| 12 |
Liu CC, Yu RX. Epistemic uncertainty in Bayesian predictive probabilities[J]. J Biopharm Stat, 2024, 34 (3): 394- 412.
doi: 10.1080/10543406.2023.2204943
|
| 13 |
Bauer P, Bretz F, Dragalin V, et al. Twenty-five years of confirmatory adaptive designs: opportunities and pitfalls[J]. Stat Med, 2016, 35 (3): 325- 347.
doi: 10.1002/sim.6472
|
| 14 |
Kunzmann K, Grayling MJ, Lee KM, et al. A review of Bayesian perspectives on sample size derivation for confirmatory trials[J]. Am Stat, 2021, 75 (4): 424- 432.
doi: 10.1080/00031305.2021.1901782
|
| 15 |
Hsiao ST, Liu L, Mehta CR. Optimal promising zone designs[J]. Biom J, 2019, 61 (5): 1175- 1186.
doi: 10.1002/bimj.201700308
|
| 16 |
Kunzmann K, Pilz M, Herrmann C, et al. The adoptr package: adaptive optimal designs for clinical trials in R[J]. J Stat Softw, 2021, 98 (9): 1- 21.
doi: 10.18637/jss.v098.i09
|
| 17 |
Mehta CR, Pocock SJ. Adaptive increase in sample size when interim results are promising: a practical guide with examples[J]. Stat Med, 2011, 30 (28): 3267- 3284.
doi: 10.1002/sim.4102
|
| 18 |
Plante M, Kwon JS, Ferguson S, et al. Simple versus radical hysterectomy in women with low-risk cervical cancer[J]. N Engl J Med, 2024, 390 (9): 819- 829.
doi: 10.1056/NEJMoa2308900
|
| 19 |
Vos MB, Van Natta ML, Blondet NM, et al. Randomized placebo-controlled trial of losartan for pediatric NAFLD[J]. Hepatology, 2022, 76 (2): 429- 444.
doi: 10.1002/hep.32403
|
| 20 |
Roeder F, Ulrich A, Habl G, et al. Clinical phase I/II trial to investigate preoperative dose-escalated intensity-modulated radiation therapy (IMRT) and intraoperative radiation therapy (IORT) in patients with retroperitoneal soft tissue sarcoma: interim analysis[J]. BMC Cancer, 2014, 14, 617.
doi: 10.1186/1471-2407-14-617
|